ParkinsonCanadaV1, France, Analysis, bibRecord, 000304

Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS

Identifieur interne : 000304 ( France/Analysis ); précédent : 000303; suivant : 000305

Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS

Auteurs : M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada]

Source :

Current pharmaceutical design [ 1381-6128 ] ; 2000.

RBID : Pascal:00-0395303

Descripteurs français

Pascal (Inist)
- Oestrogène, Article synthèse, Animal, Parkinson maladie, Hormone stéroïde, Testostérone, Démence Alzheimer, Déhydroépiandrostérone, Activité biologique, Schizophrénie, Psychose, Etat dépressif, Trouble humeur, Neuroprotecteur, Neuromodulateur, Mécanisme action, Homme, Chimiothérapie, Traitement, In vitro, In vivo.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Alzheimer Disease (drug therapy), Alzheimer disease, Animal, Animals, Biological activity, Brain (drug effects), Chemotherapy, Dehydroepiandrosterone, Dehydroepiandrosterone (therapeutic use), Depression, Depression (drug therapy), Estrogen, Estrogens (pharmacology), Estrogens (therapeutic use), Female, Human, Humans, In vitro, In vivo, Male, Mechanism of action, Mood disorder, Neuromodulator, Neuroprotective agent, Parkinson Disease (drug therapy), Parkinson disease, Prodrugs (therapeutic use), Psychosis, Review, Schizophrenia, Schizophrenia (drug therapy), Steroid hormone, Testosterone, Testosterone (therapeutic use), Treatment.
MESH :
- chemical , pharmacology : Estrogens.
- chemical , therapeutic use : Dehydroepiandrosterone, Estrogens, Prodrugs, Testosterone.
- drug effects : Brain.
- drug therapy : Alzheimer Disease, Depression, Parkinson Disease, Schizophrenia.
- Animals, Female, Humans, Male.

Abstract

Numerous reports, ranging from molecular investigations to clinical studies, demonstrate the potency of estrogens to modulate brain function and their implications in schizophrenia and depression. Alterations of dopaminergic, cholinergic, GABAergic, glutamatergic and serotonergic neurotransmission through estrogen-mediated mechanisms have been consistently established. Moreover, studies using in vivo and in vitro models as well as epidemiological data suggest that estrogens provide neuroprotection of central nervous system (CNS) cells implicated in the etiology of neurodegenerative disorders such as Alzheimer's (AD) and Parkinson's (PD) diseases. Numerous genomic or non-genomic mechanisms of actions of estrogens in the brain have been documented implicating classical nuclear estrogen receptors as well as possible estrogen membrane receptors, antioxidant activity of steroids, their effect on fluidity as well as on antiapoptotic proteins and growth factors. Selective estrogen receptor modulators (SERMs) have estrogenic and/or antiestrogenic activity depending on the target tissue. Hence, SERMs have the same beneficial effect as estrogen in skeleton and cardiovascular systems but act as antagonists in breast and uterus. The finding of beneficial side effects of SERMs in the CNS might improve their risk-benefit ratio in traditional indications. In this review, we will survey schizophrenia and depression as examples of mental diseases and AD and PD as neurodegenerative diseases. We will review brain effects of estrogens, steroids possibly acting as pro-drugs of estrogens such as testosterone and dehydroepiandrosterone (DHEA) and present novel findings with SERMs. Drugs with estrogen activity in the brain may have therapeutic potential either by modulating brain neurotransmitter transmission or through neuroprotective activity.

Affiliations:

Links to Exploration step

Pascal:00-0395303

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS</title>
<author><name sortKey="Cyr, M" sort="Cyr, M" uniqKey="Cyr M" first="M." last="Cyr">M. Cyr</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M." last="Grandbois">M. Grandbois</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S." last="Callier">S. Callier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Unit 339, St-Antoine Hospital</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>75012 Paris</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0395303</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0395303 INIST</idno>
<idno type="RBID">Pascal:00-0395303</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C78</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000046</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000B96</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B96</idno>
<idno type="wicri:doubleKey">1381-6128:2000:Cyr M:drugs:with:estrogen</idno>
<idno type="wicri:Area/Main/Merge">003B30</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10903393</idno>
<idno type="wicri:Area/PubMed/Corpus">001626</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001626</idno>
<idno type="wicri:Area/PubMed/Curation">001626</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001626</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001626</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001626</idno>
<idno type="wicri:Area/Ncbi/Merge">000110</idno>
<idno type="wicri:Area/Ncbi/Curation">000110</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000110</idno>
<idno type="wicri:doubleKey">1381-6128:2000:Cyr M:drugs:with:estrogen</idno>
<idno type="wicri:Area/Main/Merge">003896</idno>
<idno type="wicri:Area/Main/Curation">003588</idno>
<idno type="wicri:Area/Main/Exploration">003588</idno>
<idno type="wicri:Area/France/Extraction">000304</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS</title>
<author><name sortKey="Cyr, M" sort="Cyr, M" uniqKey="Cyr M" first="M." last="Cyr">M. Cyr</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M." last="Grandbois">M. Grandbois</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S." last="Callier">S. Callier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Unit 339, St-Antoine Hospital</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>75012 Paris</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, and Faculté de pharmacie Université Laval</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current pharmaceutical design</title>
<title level="j" type="abbreviated">Curr. pharm. des.</title>
<idno type="ISSN">1381-6128</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current pharmaceutical design</title>
<title level="j" type="abbreviated">Curr. pharm. des.</title>
<idno type="ISSN">1381-6128</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (drug therapy)</term>
<term>Alzheimer disease</term>
<term>Animal</term>
<term>Animals</term>
<term>Biological activity</term>
<term>Brain (drug effects)</term>
<term>Chemotherapy</term>
<term>Dehydroepiandrosterone</term>
<term>Dehydroepiandrosterone (therapeutic use)</term>
<term>Depression</term>
<term>Depression (drug therapy)</term>
<term>Estrogen</term>
<term>Estrogens (pharmacology)</term>
<term>Estrogens (therapeutic use)</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>In vitro</term>
<term>In vivo</term>
<term>Male</term>
<term>Mechanism of action</term>
<term>Mood disorder</term>
<term>Neuromodulator</term>
<term>Neuroprotective agent</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Prodrugs (therapeutic use)</term>
<term>Psychosis</term>
<term>Review</term>
<term>Schizophrenia</term>
<term>Schizophrenia (drug therapy)</term>
<term>Steroid hormone</term>
<term>Testosterone</term>
<term>Testosterone (therapeutic use)</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Estrogens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dehydroepiandrosterone</term>
<term>Estrogens</term>
<term>Prodrugs</term>
<term>Testosterone</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Alzheimer Disease</term>
<term>Depression</term>
<term>Parkinson Disease</term>
<term>Schizophrenia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Oestrogène</term>
<term>Article synthèse</term>
<term>Animal</term>
<term>Parkinson maladie</term>
<term>Hormone stéroïde</term>
<term>Testostérone</term>
<term>Démence Alzheimer</term>
<term>Déhydroépiandrostérone</term>
<term>Activité biologique</term>
<term>Schizophrénie</term>
<term>Psychose</term>
<term>Etat dépressif</term>
<term>Trouble humeur</term>
<term>Neuroprotecteur</term>
<term>Neuromodulateur</term>
<term>Mécanisme action</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>In vitro</term>
<term>In vivo</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Numerous reports, ranging from molecular investigations to clinical studies, demonstrate the potency of estrogens to modulate brain function and their implications in schizophrenia and depression. Alterations of dopaminergic, cholinergic, GABAergic, glutamatergic and serotonergic neurotransmission through estrogen-mediated mechanisms have been consistently established. Moreover, studies using in vivo and in vitro models as well as epidemiological data suggest that estrogens provide neuroprotection of central nervous system (CNS) cells implicated in the etiology of neurodegenerative disorders such as Alzheimer's (AD) and Parkinson's (PD) diseases. Numerous genomic or non-genomic mechanisms of actions of estrogens in the brain have been documented implicating classical nuclear estrogen receptors as well as possible estrogen membrane receptors, antioxidant activity of steroids, their effect on fluidity as well as on antiapoptotic proteins and growth factors. Selective estrogen receptor modulators (SERMs) have estrogenic and/or antiestrogenic activity depending on the target tissue. Hence, SERMs have the same beneficial effect as estrogen in skeleton and cardiovascular systems but act as antagonists in breast and uterus. The finding of beneficial side effects of SERMs in the CNS might improve their risk-benefit ratio in traditional indications. In this review, we will survey schizophrenia and depression as examples of mental diseases and AD and PD as neurodegenerative diseases. We will review brain effects of estrogens, steroids possibly acting as pro-drugs of estrogens such as testosterone and dehydroepiandrosterone (DHEA) and present novel findings with SERMs. Drugs with estrogen activity in the brain may have therapeutic potential either by modulating brain neurotransmitter transmission or through neuroprotective activity.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Cyr, M" sort="Cyr, M" uniqKey="Cyr M" first="M." last="Cyr">M. Cyr</name>
</noRegion>
<name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S." last="Callier">S. Callier</name>
<name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M." last="Grandbois">M. Grandbois</name>
<name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S." last="Callier">S. Callier</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000304 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000304 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:00-0395303
   |texte=   Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS

Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.